Top Industry News

Johnson & Johnson (J&J) has announced a more than $1-billion investment to build a new cell-therapy manufacturing facility in Montgomery County, Pennsylvania. The announcement is part of the company’s previously announced $55-billion investment in US-based manufacturing, research…

Monsanto, the crop-protection business of Bayer, has proposed a $7.25-billion US nationwide class settlement through a long-term claims program designed to resolve current and future claims over Roundup, a glyphosate-based herbicide, in which claimants allege Non-Hodgkin lymphoma injuries. The proposed…

The latest from CDMOs, CMOs, and suppliers featuring Recipharm, Axplora, Experic, MGS and DFE Pharma.   Chemicals/Chemical API Manufacturing * Scinai Acquires Recipharm IsraelFormulation Development/Drug Product Manufacturing * Axplora To Expand Lyophilization Capacity for ADCs* DFE Pharma Launches Continuous Manufacturing Platform * Recipharm Expanding High-Potency…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Stada, Novartis, Gilead, Eli Lilly and Company, Sanofi, and GSK. Highlights below.   For the latest news roundup on small and Emerging Pharma…

The latest from small and Emerging Pharma companies featuring EIR Biopharma, EyePoint, Korsana Biosciences, Innovacell, PharmaEssentia, Rasayana Therapeutics/Theriva Biologics, and Sensei Biotherapeutics/Faeth Therapeutics.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * EIR Biopharma Launches US IPO * EyePoint Names COO * Innovacell Launches IPO in…

Novartis has broken ground on a new biomedical research center in San Diego, California. The facility represents another milestone in the company’s $23-billion US-based investments first announced in April 2025.  Once operational in…

Sanofi has completed its $2.2-billion acquisition of Dynavax Technologies, a vaccines company. The deal was announced in January 2026.  Dynavax’s key product is its adult hepatitis B vaccine, Heplisav-B, which is marketed in the US and is differentiated by a two-dose regimen…

Eli Lilly and Company has agreed to acquire Orna Therapeutics, a bio/pharmaceutical company dedicated to engineering immune cells in vivo, for $2.4 billion.  Orna is advancing a class of therapeutics using engineered circular RNA paired…

Sanofi has appointed Belén Garijo, currently Chair and CEO of Merck KGaA, as CEO, effective April 29, 2026. She will succeed Paul Hudson, the company’s current CEO, who will remain CEO until February 17, 2026. Olivier Charmeil, currently Executive Vice President, General…

The latest from CDMOs, CMOs, and suppliers featuring Fujifilm Biotechnologies & Rentschler Biopharma.   Biologics Manufacturing * Fujifilm Biotechnologies Opens $546-M UK Biomanufacturing Expansion Appointments * Rentschler Biopharma Appoints New COO  Biologics Manufacturing  Fujifilm Biotechnologies Opens…